Literature DB >> 23404955

Alterations in adipocytokines and cGMP homeostasis in morbid obesity patients reverse after bariatric surgery.

Vicente Felipo1, Amparo Urios, Maria L García-Torres, Nisrin El Mlili, Juan A del Olmo, Miguel Civera, Joaquin Ortega, Antonio Ferrandez, Jose Martínez-Valls, Norberto Cassinello, Carmina Montoliu.   

Abstract

OBJECTIVE: Obesity-associated nonalcoholic fatty liver disease (NAFLD), covering from simple steatosis to nonalcoholic steatohepatitis (NASH), is a common cause of chronic liver disease. Aberrant production of adipocytokines seems to play a main role in most obesity-associated disorders. Changes in adipocytokines in obesity could be mediated by alterations in cyclic GMP (cGMP) homeostasis. The aims of this work were: (1) to study the role of altered cGMP homeostasis in altered adipocytokines in morbid obesity, (2) to assess whether these alterations are different in simple steatosis or NASH, and (3) to assess whether these changes reverse in obese patients after bariatric surgery. DESIGN AND METHODS: In 47 patients with morbid obesity and 45 control subjects, the levels in blood of adipocytokines, cGMP, nitric oxide (NO) metabolites, and atrial natriuretic peptide (ANP) were studied. Whether weight loss after a bariatric surgery reverses the changes in these parameters was evaluated.
RESULTS: NO metabolites and leptin increase (and adiponectin decreases) similarly in patients with steatosis or NASH, suggesting that these changes are due to morbid obesity and not to liver disease. Inflammation and cGMP homeostasis are affected both by morbid obesity and by liver disease. The increases in interleukin 6 (IL-6), interleukin 18 (IL-18), plasma cGMP, ANP, and the decrease in cGMP in lymphocytes are stronger in patients with NASH than with steatosis. All these changes reverse completely after bariatric surgery and weight loss, except IL-18.
CONCLUSION: Altered cGMP homeostasis seems to contribute more than inflammation to changes in leptin and adiponectin in morbid obesity.
Copyright © 2012 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404955     DOI: 10.1002/oby.20008

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  6 in total

1.  Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.

Authors:  Jamie E Mells; Ping P Fu; Pradeep Kumar; Tekla Smith; Saul J Karpen; Frank A Anania
Journal:  J Nutr Biochem       Date:  2014-12-06       Impact factor: 6.048

Review 2.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 3.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 4.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

5.  Changes on Adipose Tissue Distribution After Laparoscopic Roux-en-Y Gastric Bypass in Obese Göttingen Minipig. Effects on Glucose Metabolism.

Authors:  Laura Hernández Hurtado; Francisco M Sánchez-Margallo; José Luis De la Cruz Vigo; Juan Maestre Antequera; Ana M Matos Azevedo; Javier G Casado; Idoia Díaz-Güemes Martín-Portugués
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

Review 6.  Future therapy of portal hypertension in liver cirrhosis - a guess.

Authors:  Tilman Sauerbruch; Jonel Trebicka
Journal:  F1000Prime Rep       Date:  2014-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.